OncoMatch/Clinical Trials/NCT06551584
Phase I Trial for Patients w/ Advanced Hematologic Malignancies Undergoing Allogeneic HCT
Is NCT06551584 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies ORCA-T for acute myeloid leukemia.
Treatment: ORCA-T — The study goal is to characterize the safety of the combination of Orca-T with dual agent GVHD prophylaxis.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Myelodysplastic Syndrome
Demographics
Prior therapy
Cannot have received: allogeneic hematopoietic cell transplant
Lab requirements
Kidney function
Estimated glomerular filtration rate (eGFR) ≥ 50 mL/minute or creatinine < 2 mg/dL
Liver function
Total bilirubin < 2 times upper limit of normal (ULN) (patients with Gilbert's syndrome may be included once hemolysis has been excluded)
Cardiac function
Cardiac ejection fraction at rest ≥ 45% or shortening fraction of ≥ 27% by echocardiogram or radionuclide scan (MUGA)
eGFR ≥ 50 mL/minute or creatinine < 2 mg/dL; Cardiac ejection fraction at rest ≥ 45% or shortening fraction of ≥ 27% by echocardiogram or radionuclide scan (MUGA); DLCO (adjusted for hemoglobin) ≥ 50%; Total bilirubin < 2 times ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Stanford University · Palo Alto, California
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06551584 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior allogeneic hematopoietic cell transplant disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 70 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify